AbbVie Says Recent Antitrust Ruling Irrelevant In Humira Case

Law360 (May 20, 2020, 5:28 PM EDT) -- AbbVie Inc. has told an Illinois federal court that a recent ruling in a case involving speech recognition technology is not relevant whatsoever to Humira buyers' allegations that the pharmaceutical giant used a "patent thicket" to illegally delay less-expensive biosimilars for the immunosuppressant.

Humira buyers filed a notice last week arguing that a May 6 ruling from a Massachusetts federal court on a motion to dismiss antitrust claims over a company's acquisition and use of thousands of patents supports denying AbbVie's bid to duck the generic delay suit.

AbbVie responded on Tuesday that the allegations in the speech technology case —...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!